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Glioblastoma multiforme (GBM) remains the most devastating primary tumour in neuro-oncology. Targeting of the human epithelial
receptor type 2 (HER2)-neu receptor by specific antibodies is a recent well-established therapy for breast tumours. Human epithelial
receptor type 2/neu is a transmembrane tyrosine/kinase receptor that appears to be important for the regulation of cancer growth.
Human epithelial receptor type 2/neu is not expressed in the adult central nervous system, but its expression increases with the degree
of astrocytoma anaplasia. The specificity of HER2/neu for tumoral astrocytomas leads us to study in vitro treatment of GBM with anti-
HER2/neu antibody. We used human GBM cell lines expressing HER2/neu (A172 express HER2/neu more than U251MG) or not
(U87MG) and monoclonal humanised antibody against HER2/neu (Herceptin
s). Human epithelial receptor type 2/neu expression
was measured by immunohistochemistry and flow cytometry. Direct antibody effect, complement-dependent cytotoxicity and
antibody-dependent cellular cytotoxicity were evaluated by different cytometric assays. We have shown, for the first time, the ability of
anti-HER2/neu antibodies to induce apoptosis and cellular-dependent cytotoxicity of HER2/neu-expressing GBM cell lines. The results
decreased from A172 to U251 and were negative for U87MG, in accordance with the decreasing density of HER2/neu receptors.
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Glioblastomas multiforme (GBM) are the most common malignant
tumours of the central nervous system. With an incidence from 0.4
to 2.8 per year per 100000 persons (De Triboulet, 1996; Mineo et al,
2002), they are ranked fourth among the causes of death due to
cancer in the middle-aged man (Rainov et al, 1997).
Glioblastoma multiforme are partially refractory to radiation
and chemotherapy that are in standard use today (medial survival
of 18 months despite radical surgery; Hiesiger et al, 1993; Puzzili
et al, 1998). The poor effectiveness of current therapy evokes
development in areas, used for treatment of other cancers, such as
immunotherapy. Human monoclonal antibody treatment against
human epithelial receptor type 2 (HER2)/neu overexpressing
breast cancer increases patient survival (Baselga et al, 1996). The
effect of this antibody has led oncologists to prescribe immu-
notherapy in metastatic breast cancer. The HER2/neu is a 185kDa
transmembrane tyrosine/kinase receptor, which is a member of the
tyrosine kinase receptor family. It is involved in the regulation of
cell growth and in differentiation, especially during brain
embryogenesis. The HER2/neu (also called c-erbB2) receptor is
not found in the adult central nervous system (Press et al, 1990),
but it appears in tumoral astrocytes. Its expression increases with
the degree of astrocytoma anaplasia (Kristt and Yarden, 1996) and
becomes frequent in glioblastomas (20–90%; Bian et al, 2000;
Forseen et al, 2002; Koka et al, 2003). Overexpression of HER2/neu
seems correlated to higher degree of glioma cells anaplasia (Kristt
and Yarden, 1996). Activated HER2/neu can form homologous
complexes, but the major action of HER2/neu results from
heterodimerisation of HER2/neu with the other tyrosine kinase
family-activated receptors (like epidermal growth factor receptor
also called c-erbB1; Harwerth et al, 1993). Ligand–receptor
complexes that include HER2/neu appear to be more potent that
other receptor complexes and have a higher ligand affinity, a lower
rate of internalisation and degradation and a higher tyrosine
kinase activity (Sliwkowski et al, 1999). Human epithelial receptor
type 2/neu inhibition could therefore not only decrease the activity
of HER2/neu but also could affect the activity of other tyrosine
kinase receptors. Owing to the association of HER2/neu proto-
oncogene overexpression and human cancer, some monoclonal
antibodies against a panel of epitopes from HER2/neu receptor
were developed in animals. A more potent antibody for tumour
inhibition was fully humanised for human therapeutic adminis-
tration to create trastuzumab (Herceptin
s). The targeting of
HER2/neu by its specific antibody is known to have antitumoral
effect in breast cancer (Pietras et al, 1998; Spiridon et al, 2002).
The activated antibody containing human Fc region can generate
two cytolytic pathways against the target cells by the activation of
the complement cascade and antibody-dependent cellular cyto-
toxicity (ADCC). The ADCC is triggered by interaction between
antibody-coated target cells and Fc receptor type III (CD16) on
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seffector cells (Carter et al, 1992), and as resting microglia cells are
found to express constitutively Fc receptors, local ADCC (Vedeler
et al, 1994) could be induced by trastuzumab in the brain.
Moreover, intravital fluorescence microscopical approach demon-
strates that glioma microvascularisation produces an abnormal
blood–brain barrier. The intravital approach (Vajkoczy et al,
1998) shows an intratumoral homogeneous extravasation of a 150-
kDa protein (weight of IgG).
In our study, Herceptin
s induces GBM cell lines apoptosis and
ADCC. These effects are correlated to HER2/neu expression. These
results suggest that HER2/neu might be a useful tumour-specific
target for antibody-mediated therapy.
MATERIALS AND METHODS
Cells lines
The GBM cell lines were grown in Dulbecco’s modified Eagle’s
medium (Gibco, Paisley, Scotland) supplemented with 10% heat-
inactivated foetal calf serum (Gibco, Paisley, Scotland), 1% L-
glutamine (Eurobio), 100UIml
 1 penicillin G and 100mgml
 1
streptomycin (Eurobio) and maintained at 371C in a humid
atmosphere of 5% CO2 in air. Before the experiments, cells were
harvested by 0.05% trypsin and 0.02% EDTA (Eurobio) at 371C;
their viability was more than 95% as assessed by the trypan blue
technique. The U87MG, A172 and U251MG human glioblastoma
cell lines were kindly provided, respectively, by F Furnari (Ludwig
Institute For Cancer Research, La Jolla, CA, USA), JL Fischel
(Centre A Lacassagne, Nice, France) and A Gatignol (Lady Davis
Institute for Medical Research, Montreal, Quebec, Canada).
Monoclonal antibody
Herceptin
s (trastuzumab, Genentech, Roche Laboratory) is a
humanised monoclonal immunoglobulin G against HER2/neu
extracellular epitope (amino acids 529–627). It derivates from a
murine antibody (called 4D5 (Fendly et al, 1990; Lewis et al, 1993)
and it was humanised for clinical administration. The hypervari-
able domain remains similar to the animal domain, but the other
95% is similar to human IgG1. For experimental use, Herceptin
s,
in lyophilised form, was weighted daily, and suspended in
phosphate-buffered saline (PBS).
Immunohistochemistry
Sections of cellular pellet were exposed to hydrogen peroxide to
reduce endogenous peroxidase activity and then exposed to pig
serum to block the nonspecific protein binding. The sections were
incubated with a rabbit anti-human polyclonal antibody against
HER2/neu oncoprotein (Dakocytomation, Denmark) diluted 1:250
in PBS 0.1 M 30min at room temperature. After three rinses in the
same buffer, the sections were incubated with a polymer
conjugated with peroxidase and anti-rabbit immunoglobulins.
Colour was developed by incubation with diaminobenzidine and
H2O2. Finally, the sections were washed in PBS, dehydrated and
coverslips were added for optical microscopy.
Flow cytometry analysis
A total of 2 10
5 cells were labelled for 30min at 41C with 10mgo f
Herceptin
s, washed twice by PBS supplemented with 1% bovine
serum albumin (PBS-BSA), then incubated with fluorescein
isothiocyanate (FITC)-conjugated rabbit anti-human IgG (1:10
dilution, 30min at 41C) (Dakocytomation, Denmark). Two washes
were carried out again before cytometric analysis.
The complement inhibitors, CD55 (decay accelerating factor),
CD59 (Protectin) and CD45 (complement receptor type 1) were
detected at the cell surface as in the previous experiment. We used
the following antibodies: FITC-labelled mouse anti-human CD55
(Beckman Coulter), FITC-conjugated mouse anti-human CD45
(Beckman Coulter) and unconjugated mouse anti-human CD59
(Beckman Coulter) revelled by a phycoerythrin (PE)-conjugated
goat anti-mouse IgG. Per experiment, 5000 cells were analysed in a
flow cytometer (Beckman Coulter) equipped with a 500mW argon
laser. The flow cytometer settings selected were controlled by using
unstained cells and isotype-matched nonreactive FITC Mabs. The
number of fluorescent molecules per cell were indirectly measured
by assessing the mean fluorescence intensity (MFI) of cells
analysed in each test.
Identification of apoptotic cells
The phosphatidyl serine (PS) translocation to the outer face of the
membrane was visualised by the binding of Annexin V. A total of
105 cells in 1ml culture medium were treated with 1ml of different
concentrations of Herceptin
s. After 6, 12 or 24h incubation at
371C, cells were washed in PBS and stained with FITC–Annexin V
and propidium iodide (PI) according to the manufacturer’s
instructions (Beckman Coulter). PI was used to exclude dead
cells. Percentages of apoptotic cells (Annexin V-positive cells) were
thus calculated within the PI-negative population of cells. To
analyse the different data, some results were expressed as the
percentage of variation which is equal to
100
Herceptin concentration-treatedapoptoticcells% control-treatedapoptoticcells%
control-treatedapoptoticcells%
 
Complement-dependent cytotoxicity assay
To study the effect of Herceptin
s in inducing the activation of
complement, 10
5 cells were incubated for 6, 12 or 24h with
different Herceptin
s concentrations containing 15% of AB human
serum (used as source of complement and given by volunteers and
consent donors of the Transfusion Center, Brest). The cells were
removed and PI was added for 10min at 41C before cytometric
analysis.
Antibody-dependent cellular cytotoxicity assay
The peripheral large granular lymphocytes (LGL, including natural
killer lymphocytes), used as human effector cells, were separated
from the blood of healthy donors in density gradients (first on
Ficoll–Hypaque density gradients and then on Percoll (Pharma-
cia) density gradients). A total of 2 104 GBM cells (targets) and
LGL (effectors) were mixed in 1ml culture medium (ratio targets/
effectors 1/75 or 1/100) and then incubated for 6h at 371C with
1ml of antibodies. To stain effectors, we incubated the washed
cells with 5mg of FITC-conjugated anti-human CD45 antibodies for
30min at room temperature (CD45 is not present on glioblastomas
cells). Two further rinses in PBS were carried out before cytometric
analysis, cells were then incubated for 10min at 41C with 10mgo f
PI to determine the percentages of dead cells.
Statistical analysis
The data were analysed for significance by Student’s t-test.
RESULTS
GBM cell lines express HER2/neu
Human epithelial receptor type 2/neu membranous density was
evaluated by immunohistochemistry (IHC) and flow cytometry.
Histopathologists classified immunostaining as follows (as used
for breast cancer): 0¼no staining; 1þ¼faint, incomplete
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smembranous pattern; 2þ¼moderate, complete membranous
pattern; and 3þ¼strong membranous pattern (Forseen et al,
2002). For the cytometric assay, the density was estimated by
comparative method between the MFI of isotype control and the
MFI after HER2/neu-FITC staining. BT474 is an overexpressing
3þ breast cancer cell line used as reference in most studies. Its
MFI was 20. By cytometry, the MFI of A172 cell line was 4; this cell
line was classified þ by HIC. The MFI of U251 cell line was 2,
indicating a less important intensity of HER2/neu molecule per cell
than for A172; U251MG was classified 0 by HIC. Based on these
two different techniques, we noted that U87MG cell line showed no
membranous HER2/neu positivity (Table 1). The effect of
Herceptin
s was tested on the U251MG and A172 cell lines. The
U87MG cell line was used as a negative cell line for the expression
of HER2/neu.
Anti-HER2/neu antibody induces glioblastomas cells
apoptosis
Herceptin
s induces the apoptosis of GBM cell lines expressing
HER2/neu, as shown by staining by Annexin V of A172 cells
incubated with anti-HER2/neu antibody and nearly no staining by
PI (Figure 1). Best results were obtained at 24-h cell incubation
with antibodies (6h tests showed less activity and 48h tests did not
show higher apoptosis; Figure 1C). When mixed with A172 cell
line, the efficiency of the antibody increased with the antibody
concentration until 25mgml
 1 and then decreased (probably
corresponding to the saturation of antibody recognition sites).
The spontaneous apoptosis without antibody of 10 tests were
compared by Student’s t-test to the apoptosis with 25mgml
 1 of
antibody, the test was significant with Po0.01. With U251MG cell
line, the highest activity was observed with 50mgml
 1l (compar-
ison between the apoptosis without or with 50mgml
 1 of antibody
of five tests was significant with Po0.05, Figure 2). Moreover, the
higher apoptosis induction was obtained in the A172 cell line than
in the U251MG cell line. No apoptosis induction was found for
U87MG cell line. The apoptosis induction decreases in accordance
with the density of HER2/neu receptors.
Complement-dependent cytotoxicity assay
We wanted to evaluate the ability of Herceptin
s to induce
complement-mediated cytotoxicity on HER2/neu-expressing GBM
cell lines. For this purpose, human serum AB (used as source of
complement) was added to the medium with antibodies, but it did
not increase cell death induction. The inefficiency of complement-
mediated cytotoxicity was explained by a strong expression of
complement inhibitory factors (CD55 and CD59 on A172 and
U251MG cell lines, data not shown).
ADCC of anti-HER2/neu antibody
During ADCC assay establishment, we measured the density of
membranous CD45. We observed that this molecule was highly
expressed by effector cytotoxic cells. This allowed us to
differentiate the two cellular types (GBM and effectors; Figure 3)
and to analyse ADCC (Figure 4). In order to determine the level of
cytotoxicity induced by the antibody and by the effectors alone,
control tests were performed using Herceptin
s alone
without effectors and effectors alone without antibody.
Herceptin
s did not induce apoptosis in U87MG cell line and
ADCC was not tested for this cell line. During this assay, we
observed that ADCC was already presented using 1mgml
 1 of
antibody (comparison between the cellular death without or with
1mgml
 1 of antibody of five tests was significant with Po0.05)
and was still moderately increased with higher concentrations
(Figure 4C). Moreover, as apoptosis was mediated by Herceptin
s,
more cytotoxicity was induced in A172 cell line than in U251MG
Table 1 Evaluation of HER2/neu expression on glioblastoma cell lines by
IHC and by flow cytometry
HER2/neu expression
Cell lines Species IHC Flow cytometry
GL15 Human   
U87 Human   
8MG Human   Weak
LN18 Human   Weak
T98G Human   Weak
U251MG Human   +
A172 Human + ++
BT474 Human/breast +++ +++
HER2¼human epithelial receptor type 2; IHC¼immunohistochemistry.
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Figure 1 Apoptosis induction: The A172 cell line expressing HER2/neu
undergo apoptosis, following incubation with Herceptin
s. Cells were
incubated for 24h with medium (A) or with 25mg of Herceptin
s (B). The
cells staining with FITC-conjugated Annexin V and PI. Apoptotic cells were
identified as Annexin V positive and PI negative. (C) Time course analysis of
PS exposure after incubation of A172 cell line Herceptin
s 25mgml
 1.
Only 24h results are statistically significant (Po0.01).
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Figure 2 Increasing apoptosis in glioblastomas cell lines expressing
HER2/neu: Cells were incubated for 24h with different concentrations of
Herceptin
s.
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scell line. Similar results were obtained with target/effector ratios of
1/75 and 1/100.
DISCUSSION
This study demonstrates, for the first time, the ability of Herceptin
s
to induce in vitro apoptosis of HER2/neu-expressing GBM.
Of the cases studied (results from tumour biopsy), the range in
results observed for HER2/neu in vivo positivity is wide (20–90%).
Some authors detect HER2/neu positivity without density analysis
of receptors, so they report more than 70% positivity (Dietzmann
and Von Bossanyi, 1994; Kristt and Yarden, 1996; Westphal et al,
1997; Bian et al, 2000). Some authors consider only the 2þ and
3þ tumours as positive, so they report only 20% positivity
(Forseen et al, 2002; Koka et al, 2003).
The low number of cell lines overexpressing HER2/neu in vitro
was unexpected (more than 70% in vivo positivity and only 2
positivity from seven different human cell lines, Table 1). Random
selection may explain the difference but it seems that very few cell
lines in vitro overexpress tyrosine kinase receptors I (EGFR) or II
(HER2/neu (Thomas et al, 2003). Some authors report decreasing
of tyrosine kinase receptor cellular density during long in vitro
culture and increasing receptor density on in vivo implantation
(Fischel, 2003). Paracrine stimulation of the receptor by its ligand
in vivo could explain this difference.
The effect of Herceptin
s was first demonstrated for breast cancer
(Pegram et al, 1999), then apoptotic effects were reported in
different cancers (Bu ¨chler et al, 2001; Fujimura et al, 2002; Kono
et al, 2002). We report similar results with GBM cell lines:
Herceptin
s induces a significant apoptosis induction at 24h. Most
studies reported significant results after 72h except one on ovarian
adenocarcinoma, which was significant after 24h (Fujimura et al,
2002). Two factors could explain this faster effect on GBM cell lines.
First, GBM is a very aggressive tumour with a short doubling time.
These particular high kinetics could explain an earlier effect.
Second, we used Annexin V–IP assay that could be positive earlier
than thymidine incorporation assay often describes in other studies.
We obtained greatest apoptosis induction in the A172 cell line
than in U251 cell line and no apoptosis in the U87MG cell line. In
the same way, the HER2/neu receptor density decreases from the
A172 cell line to negative for U87MG. In our study, the effect of
Herceptin
s was correlated with the HER2/neu receptors density.
This correlation was previously reported for breast, gastric and
ovarian tumours (Bu ¨chler et al, 2001; Fujimura et al, 2002).
Moreover, we report less apoptosis or cytotoxicity induction by
antibodies with GBM cell lines than in most other publications
about Herceptin
s in other cancer cell lines. The cell lines we used,
however, exhibited less HER2/neu overexpression than most other
cell lines usually tested with Herceptin
s. The MFI of BT474 breast
cancer cell lines was with our technical conditions of 20. The MFI
of A172 cell line was 4 and the MFI of U251MG cell line was 2. The
ability of Herceptin
s to induce apoptosis or cytotoxicity seems to
be correlated with HER2/neu receptor density in cancer cell lines
from the same organ, so the lower receptor density of our cancer
cell lines could explain the lower activity of Herceptin
s.
Furthermore, Herceptin
s is known to induce ADCC in different
organ cancer cell lines (Carter et al, 1992; Sliwkowski et al, 1999).
We report the ability of Herceptin
s to induce ADCC with higher
cytotoxicity in the A172 cell line than the U251MG cell line. The
antibody inducing ADCC is again higher in the cell line with the
highest HER2/neu density. This result suggests a correlation
between the HER2/neu receptors density and the effect of ADCC.
Similar correlation was reported for gastric adenocarcinomas
(Pegram et al, 1999). Microglia was found to make up 7.5–9% of
the total glial population in white matter (Akiyama and Mc Geer,
1990). These cells have a leucocyte origin (Flugel et al, 2001),
phagocytic function and can produce a cytotoxic action when
triggered by antibody coated through Fc gamma receptors (Peress
et al, 1993; Vedeler et al, 1994). Proteins (150kDa) such as IgG are
supposed to cross the abnormal GBM blood–brain barrier
(Vajkoczy et al, 1998). The ability of IgG against EGFR to cross
the blood brain barrier was confirmed by a phase I study (Faillot
et al, 1996). Herceptin
s could interact with microglia to produce
ADCC in vivo.
Adding human serum did not induce cytotoxicity in our GBM cell
lines. However, the ability of Herceptin
s to induce cytotoxicity with
complement is well established (Niculescu et al,1 9 9 2 ) .W ee x p l a i n
the lack of effect to the overexpression by A172 and U251MG cell
lines of the two complement inhibitors: CD55 and CD59.
We have shown the efficacy of Herceptin
s to induce apoptosis
against relative low HER2/neu-overexpressing GBM cell lines by
 CD45 expression
 CD45−FITC
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cells
10
0
1028
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3
Figure 3 CD45 expression on the GBM cell lines and leucocytes: Cells
were stained by FITC-conjugated mouse anti-human CD45 for 30min at
41C. Flow cytometry allowed us to differentiate the glioblastoma and
effector cells.
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Figure 4 Antibody-dependent cellular cytotoxicity of Herceptin
s
against A172 cell line. Target cells were incubated with effector cells (ratio
targets/effectors 1/75) for 6h with medium only (A) or with 10mgml
 1 of
Herceptin
s (B). FITC labelled anti-human CD45 antibody then PI was
added. Analysis was based on the negative A172 population CD45
determination. The dead cells were stained by PI (C).
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sclassical IHC. No induction of apoptosis was observed for breast
cell lines with such level of HER2/neu expression. It is known that
one of the differences between GBM and other cancers is the
absence of expression of HER2/neu on the surface of normal glial
tissue. Cells from other normal organ (breast or ovarian) express a
weak density of HER2/neu. This difference could explain the
greater importance of HER2/neu activity on GBM physiology and
the greater effect of its blockage. Moreover, the effect of
Herceptin
s could be increased by synergistic effects with several
chemotherapies (as etoposide or cisplatin; Pegram et al, 1999).
Finally, the evidence of Herceptin’s ability to induce apoptosis
or cytotoxicity in GBM cell lines overexpressing HER2/neu made
us commence animal experiments in the following months.
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